Roberta Caputo
45 Papers
85 Citations
Roberta Caputo is an academic researcher. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 11, co-authored 19 publications.
Chat about Author
Papers
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Fortunato Ciardiello,Roberto Bianco,Roberta Caputo,Rosa Caputo,Vincenzo Damiano,Teresa Troiani,Davide Melisi,Ferdinando De Vita,Sabino De Placido,A. Raffaele Bianco,Giampaolo Tortora +10 more
TL;DR: Long-term treatment of GEO xenografts with selective EGFR inhibitors results in the development of EGFR inhibitor-resistant cancer cells, indicating that inhibition of VEGF signaling has potential as an anticancer strategy, even in tumors that are resistant to EGF inhibitors.
367
•Journal Article
Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase
Fortunato Ciardiello,Rosa Caputo,Vincenzo Damiano,Roberta Caputo,Teresa Troiani,Donatella Vitagliano,Francesca Carlomagno,Bianca Maria Veneziani,Gabriella Fontanini,A. Raffaele Bianco,Giampaolo Tortora +10 more
TL;DR: This study suggests that in addition to inhibiting endothelial cell proliferation by blocking VEGF-induced signaling, ZD6474 may also be able to inhibit cancer cell growth by blocking EGFR autocrine signaling.
348
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
Michela Piezzo,Stefania Cocco,Roberta Caputo,Daniela Cianniello,Germira Di Gioia,Vincenzo Di Lauro,Giuseppina Fusco,Claudia Martinelli,Francesco Nuzzo,Matilde Pensabene,Michelino De Laurentiis +10 more
TL;DR: This review summarizes the available knowledge regarding CDK4/6 inhibitor, the discovery of new biomarkers of response, and the biological rationale for new combination strategies of treatment.
126
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Michela Piezzo,Paolo Chiodini,Maria Antonietta Riemma,Stefania Cocco,Roberta Caputo,Daniela Cianniello,Germira Di Gioia,Vincenzo Di Lauro,Francesca Di Rella,Giuseppina Fusco,Giovanni Iodice,Francesco Nuzzo,Carmen Pacilio,Matilde Pensabene,Michelino De Laurentiis +14 more
TL;DR: This meta-analysis of randomized controlled trials (RCTs) is aimed to better characterize the efficacy of CDK4/6 inhibitors in some relevant subgroups and to test heterogeneity between different compounds with a particular focus on their ability to improve overall survival (OS).
•Journal Article
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Giampaolo Tortora,Rosa Caputo,Vincenzo Damiano,Roberta Caputo,Teresa Troiani,Bianca Maria Veneziani,Sabino De Placido,Angelo Raffaele Bianco,Uwe Zangemeister-Wittke,Fortunato Ciardiello +9 more
TL;DR: The combination of 4625, AS-PKAI, and ZD1839 resulted in a strong antiproliferative, proapoptotic, and antiangiogenic response, suggestive of a functional interaction between EGFR, PK AI, and bcl-2/bcl-xL and providing a rationale for the selection of specific molecular treatments for the development of therapeutic strategies.
56